AU2002239414A1 - Modified plasminogen related peptide fragments and their use as angiogenesis inhibitors - Google Patents

Modified plasminogen related peptide fragments and their use as angiogenesis inhibitors

Info

Publication number
AU2002239414A1
AU2002239414A1 AU2002239414A AU3941402A AU2002239414A1 AU 2002239414 A1 AU2002239414 A1 AU 2002239414A1 AU 2002239414 A AU2002239414 A AU 2002239414A AU 3941402 A AU3941402 A AU 3941402A AU 2002239414 A1 AU2002239414 A1 AU 2002239414A1
Authority
AU
Australia
Prior art keywords
peptide fragments
related peptide
angiogenesis inhibitors
modified plasminogen
plasminogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002239414A
Inventor
Weidong Richard Ji
Chester A. Meyers
Sesha J. Natarajan
Pamela Trail
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of AU2002239414A1 publication Critical patent/AU2002239414A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6435—Plasmin (3.4.21.7), i.e. fibrinolysin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21007—Plasmin (3.4.21.7), i.e. fibrinolysin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5029—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on cell motility
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5064—Endothelial cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/20—Screening for compounds of potential therapeutic value cell-free systems
AU2002239414A 2000-11-02 2001-10-31 Modified plasminogen related peptide fragments and their use as angiogenesis inhibitors Abandoned AU2002239414A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24538400P 2000-11-02 2000-11-02
US60/245,384 2000-11-02
PCT/US2001/045183 WO2002040510A2 (en) 2000-11-02 2001-10-31 Modified plasminogen related peptide fragments and their use as angiogenesis inhibitors

Publications (1)

Publication Number Publication Date
AU2002239414A1 true AU2002239414A1 (en) 2002-05-27

Family

ID=22926448

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002239414A Abandoned AU2002239414A1 (en) 2000-11-02 2001-10-31 Modified plasminogen related peptide fragments and their use as angiogenesis inhibitors

Country Status (3)

Country Link
US (1) US20030054988A1 (en)
AU (1) AU2002239414A1 (en)
WO (1) WO2002040510A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106928316B (en) * 2015-12-31 2020-11-20 深圳翰宇药业股份有限公司 Method for purifying and oxidizing disulfide bond-containing polypeptide
TWI677348B (en) 2016-12-15 2019-11-21 大陸商深圳瑞健生命科學研究院有限公司 A way to improve heart disease
CA3047167A1 (en) * 2016-12-15 2018-06-21 Talengen International Limited Method for treating and preventing atherosclerosis and complications thereof
EP3556380A4 (en) * 2016-12-15 2020-05-13 Talengen International Limited Method for preventing and treating tissue and organ fibrosis
EP3556379A4 (en) 2016-12-15 2020-08-19 Talengen International Limited Method and drug for preventing and treating obesity
EP3643321A4 (en) 2017-06-19 2021-05-05 Talengen International Limited Method for regulating and controling glp-1/glp-1r and drug

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2240296C (en) * 1995-12-13 2004-05-04 The Children's Medical Center Corporation Endothelial cell proliferation inhibitor and method of use
US5801146A (en) * 1996-05-03 1998-09-01 Abbott Laboratories Compound and method for inhibiting angiogenesis
AU4445100A (en) * 1999-04-14 2000-11-14 Karolinska Innovations Ab Kringle domains of plasminogen, capable of modulating angiogenesis in vivo
JP4209086B2 (en) * 1999-05-17 2009-01-14 コンジュケム バイオテクノロジーズ インコーポレイテッド Long-lasting anti-angiogenic peptide
EP1591453A1 (en) * 1999-05-17 2005-11-02 ConjuChem Inc. Modified peptides yy and conjugates thereof

Also Published As

Publication number Publication date
US20030054988A1 (en) 2003-03-20
WO2002040510A2 (en) 2002-05-23
WO2002040510A3 (en) 2003-06-05

Similar Documents

Publication Publication Date Title
AU2001249670A1 (en) Substituted thiazoles and the use thereof as inhibitors of plasminogen activatorinhibitor-1
HUP0300855A3 (en) Peptidmomimetic protease inhibitors, pharmaceutical compositions and their use
AU2001265008A1 (en) Caspase inhibitors and uses thereof
HUP0300720A3 (en) Serine protease inhibitors, pharmaceutical compositions containing them and their use
AU2001249969A1 (en) Inha inhibitors and their use as antibacterials
AU2001270260A1 (en) 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors
AU2002356762A1 (en) 4-arylquinazolines and use thereof as nhe-3 inhibitors
AU2002230836A1 (en) Benzylamine derivatives and their use as thrombin inhibitors
AU2001285750A1 (en) Urokinase inhibitors
AU6379101A (en) Highly selective inhibitors of the urokinase plasminogen activator
AU2001294557A1 (en) Thrombin inhibitors
AU2002216649A1 (en) Benzoxazole lpaat- beta inhibitors and uses thereof
AU2002224553A1 (en) Human proteases
AU2002230953A1 (en) Recombinant phytases and uses thereof
AU2002241661A1 (en) Multifunctional protease inhibitors and their use in treatment of disease
AU6536200A (en) Proteases and protease inhibitors
IL152396A0 (en) New thiochromane derivatives derivatives and their use as thrombin inhibitors
AU2001251115A1 (en) Use of locally applied dna fragments
AU2001261737A1 (en) Methods and compositions for promoting angiogenesis using monocytes
AU2002239414A1 (en) Modified plasminogen related peptide fragments and their use as angiogenesis inhibitors
AU2002223313A1 (en) Protease inhibitors and their pharmaceutical uses
AU2001249409A1 (en) Ricin inhibitors and methods for use thereof
AU2001277561A1 (en) Biphenyl derivatives and the use thereof as integrin inhibitors
AU1039801A (en) Compounds and their use as cysteine protease inhibitors
AU2001242502A1 (en) Use of protease inhibitors in cosmetics and pharmacy